[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Zhang et al., 2023 - Google Patents

Nanoscintillator‐Mediated X‐Ray‐Triggered Boosting Transformation of Fe3+ into Fe2+ for Enhancing Tumor Ferroptosis/Immunotherapy

Zhang et al., 2023

Document ID
18438983976173823635
Author
Zhang C
Lu S
Deng K
Qian W
Liu Y
Li Y
Jin S
Suo R
Xu H
Wu B
Publication year
Publication venue
Advanced Functional Materials

External Links

Snippet

Ferroptosis therapy induced by iron‐catalyzed Fenton reaction has offered enormous opportunities for tumor therapy. Unfortunately, high catalytic activity ferrous (Fe2+)‐based therapeutic agent has remained challenging due to the instability of Fe2+. Herein, an X‐ray …
Continue reading at advanced.onlinelibrary.wiley.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
    • A61K47/48853—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere
    • A61K47/48861—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere the form being an inorganic particle, e.g. a ceramic particle, silica particle, ferrite, synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1077—Beam delivery systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1203—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules in a form not provided for by groups A61K51/1206 - A61K51/1296, e.g. cells, cell fragments, viruses, virus capsides, ghosts, red blood cells, viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1085—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy characterised by the type of particles applied to the patient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients

Similar Documents

Publication Publication Date Title
Ning et al. Type-I AIE photosensitizer loaded biomimetic system boosting cuproptosis to inhibit breast cancer metastasis and rechallenge
Wu et al. Copper‐enriched prussian blue nanomedicine for in situ disulfiram toxification and photothermal antitumor amplification
Fan et al. Modulation of intracellular oxygen pressure by dual‐drug nanoparticles to enhance photodynamic therapy
Dou et al. Radiation-responsive scintillating nanotheranostics for reduced hypoxic radioresistance under ROS/NO-mediated tumor microenvironment regulation
Sun et al. Nanoscintillator-mediated X-ray induced photodynamic therapy for deep-seated tumors: from concept to biomedical applications
Du et al. X‐ray‐controlled generation of peroxynitrite based on nanosized LiLuF4: Ce3+ scintillators and their applications for radiosensitization
Yang et al. Photothermo‐promoted nanocatalysis combined with H2S‐mediated respiration inhibition for efficient cancer therapy
Sivasubramanian et al. Evolution of nanoparticle-mediated photodynamic therapy: from superficial to deep-seated cancers
Song et al. Near‐infrared light‐triggered chlorine radical (. Cl) stress for cancer therapy
He et al. Recent progress and trends in X-ray-induced photodynamic therapy with low radiation doses
Zhang et al. Nanoscintillator‐Mediated X‐Ray‐Triggered Boosting Transformation of Fe3+ into Fe2+ for Enhancing Tumor Ferroptosis/Immunotherapy
Wu et al. In vivo X‐ray triggered catalysis of H2 generation for cancer synergistic gas radiotherapy
Zhang et al. Enhanced tumor accumulation of sub‐2 nm gold nanoclusters for cancer radiation therapy
Pan et al. X‐Ray‐Responsive zeolitic imidazolate framework‐capped nanotherapeutics for cervical cancer‐targeting radiosensitization
Xu et al. Monte Carlo Simulation‐Guided Design of a Thorium‐Based Metal–Organic Framework for Efficient Radiotherapy‐Radiodynamic Therapy
Zhang et al. Low-dose x-ray excited photodynamic therapy based on naluf4: Tb 3+–rose bengal nanocomposite
US10525146B2 (en) Metal oxide nanoparticle for cell lysis
Yu et al. Pure Organic AIE Nanoscintillator for X‐ray Mediated Type I and Type II Photodynamic Therapy
Zhang et al. Novel FeF2/Fe1–xS Nanoreactor‐Mediated Mitochondrial Dysfunction via Oxidative Stress and Fluoride Ions Overloaded for Synergistic Chemodynamic Therapy and Photothermal Therapy
Crapanzano et al. Co-adjuvant nanoparticles for radiotherapy treatments of oncological diseases
Ma et al. Combinational phototherapy and hypoxia-activated chemotherapy favoring antitumor immune responses
Nguyen et al. Amplified fenton-based oxidative stress utilizing ultraviolet upconversion luminescence-fueled nanoreactors for apoptosis-strengthened ferroptosis anticancer therapy
Varzandeh et al. Application of nano‐radiosensitizers in combination cancer therapy
Pan et al. Near‐infrared laser‐activated aggregation‐induced emission nanoparticles boost tumor carbonyl stress and immunotherapy of breast cancer
Souris et al. X-ray activated nanoplatforms for deep tissue photodynamic therapy